ADMA Biologics Stock (NASDAQ:ADMA), Trade Ideas

ADMA Biologics

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

News

Small Cap

Markets

Trading Ideas

ADMA

ANIP

Bristol-Myers Squibb Company (NYSE: BMY) reported an adjusted loss per share of $4.40, narrower than the Zacks Consensus Estimate of a loss of $4.53 per share. In the year-ago quarter, BMY posted adjusted earnings per share of $2.05.

Bristol-Myers Q1 Loss Narrower Than Expected, Sales Beat

Health Care

General

MRNA

Shares of Moderna (NASDAQ: MRNA) rose 6.2% on Apr 9 after management announced encouraging data from a portion of an early-stage study on mRNA-4157/V940, its investigational individualized neoantigen therapy, in certain patients with head and neck cancer.

Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study

Penny Stocks

Intraday Update

Movers

AVGO

BLUE

CVNA

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

FYBR

GOEV

HROW

IBRX

LUMN

NTRS

PTON

PTRA

RBBN

RXRX

WPRT

U.S. stocks traded higher, with the Dow Jones gaining over 250 points on Wednesday. Here are some big stocks recording gains in today’s session.

AT&amp;T, Carvana, Northern Trust, And Other Big Stocks Moving Higher On Wednesday

ADMA Biologics Inc

<p><strong>Bristol-Myers Squibb Company</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bmy#NYSE">BMY</a>) reported an adjusted loss per share of $4.40, narrower than the Zacks Consensus Estimate of a loss of $4.53 per share. In the year-ago quarter, BMY posted adjusted earnings per share of $2.05.</p>
<p>The year-over-year deterioration can be attributed to higher acquired IPRD costs, reflecting the impact of recent acquisitions and an increase in operating expenses.&nbsp; The bottom-line was also negatively impacted due to higher interest expenses resulting from new debt issuance to fund recent acquisitions.</p>
<p>Total revenues of $11.9 billion surpassed the Zacks Consensus Estimate of $11.4 billion. Revenues also increased 5% from the year-ago period&#39;s level, primarily driven by Eliquis, Reblozyl and Opdualag&#39;s encouraging performance.&nbsp; However, this was partially offset by a decline in the sales of Opdivo and Revlimid.</p>
<p>The stock is trading down following the quarterly earnings release.</p>
<p>The company&#39;s shares have lost 4.8% year to date compared with the industry&#39;s decline of 9.4%.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/5c/65692.jpg?v=642424254" /><br />
Image Source: Zacks Investment Research</p>
<h3>Quarterly Details</h3>
<p>Revenues increased 7% to $8.5 billion in the United States due to higher sales of Eliquis, Reblozyl and Opdualag. However, Opdivo revenues were down 10% to $1.2 billion due to inventory and the timing of orders. Lower sales of the multiple myeloma&nbsp;drug Revlimid also adversely impacted top-line growth.</p>
<p>International revenues were flat year over year at $3.4 billion due to lower average net selling prices. The negative impact from foreign exchange was 5%.</p>
<h3>Growth Portfolio Revenues</h3>
<p>Revenues from the Growth portfolio totaled $4.8 billion, up 8% from the year-ago level. The top line grew 11% year over year when adjusted for foreign exchange impacts. Growth Portfolio revenues were primarily driven by higher demand for Reblozyl, Opdualag, Yervoy, Camzyos, and Sotyktu, partially offset by Opdivo and Abecma.</p>
<p>Total sales of the immuno-oncology drug Opdivo, approved for multiple cancer indications, went down 6% year over year to $2.1 billion. The figure also missed the Zacks Consensus Estimate and our estimate of $2.3 billion and $2.33 billion, respectively.</p>
<p>Sales of the rheumatoid arthritis drug Orencia increased 4% to $798 million.<br />
Melanoma drug Yervoy contributed $583 million to the top line, up 15% year over year.</p>
<p>Reblozyl sales surged 72% year over year to $354 million. The drug&#39;s label was expanded in the European Union to include the first-line treatment of adult patients with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes.</p>
<p>Reblozyl sales beat the Zacks Consensus Estimate and our estimate of $325 million and $341.5 million, respectively.</p>
<p>Opdualag sales jumped 76% to $206 million.</p>
<p>Zeposia sales rose 41% to $110 million and Breyanzi sales rallied 51% to reach $107 million.&nbsp; Camzyos and Sotyktu sales totaled $84 million and $44 million, respectively.</p>
<p>Augtyro and Krazati raked in sales of $6 million and $21 million, respectively.<br />
However, Abecma sales declined 44% to $82 million.&nbsp;</p>
<h3>Legacy Portfolio Revenues</h3>
<p>Revenues for the Legacy Portfolio in the first quarter totaled $7.1 billion, up 2% year over year. This was driven by a 9% increase in global sales of blood thinner drug Eliquis.</p>
<p>Eliquis sales of $3.7 billion also beat the Zacks Consensus Estimate and our model estimate of $3.6 billion.</p>
<p>Please note that Bristol-Myers has a collaboration agreement with <strong>Pfizer</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>) for Eliquis. The companies collaborated in 2007. Profits and losses are shared equally on a global basis, except in certain countries where Pfizer commercializes Eliquis and pays BMY a sales-based fee.</p>
<p>MM drug, Pomalyst, generated sales of $865 million, up 4% year over year.</p>
<p>Leukemia drug Sprycel generated sales of $374 million, down 13% year over year due to a 34% decline in international sales.</p>
<p>Revlimid revenues declined 5% to $1.67 billion. This was due to lower demand owing to generic erosion. The top line surpassed the Zacks Consensus Estimate of $1.23 billion and our estimate of $1.16 billion. Abraxane revenues declined 9% to $217 million.</p>
<h3>Costs Increase</h3>
<p>Gross margin fell to 75.5% from 77.8% in the year-ago quarter due to product mix. Adjusted research and development expenses increased 6% to $2.3 billion, primarily due to the impact of recent acquisitions and higher costs to support the overall portfolio.&nbsp; Adjusted marketing, selling and administrative expenses increased 13% to $2 billion, primarily due to the timing of spend and the impact of recent acquisitions.</p>
<p>Acquired IPRD increased to $12.9 billion from $75 million, primarily due to the Karuna asset acquisition and SystImmune collaboration.</p>
<h3>2024 Guidance Update</h3>
<p>Bristol-Myers now expects adjusted earnings in the range of $0.40-$0.70 in 2024, down from the earlier estimate of $7.10-$7.40, to reflect the dilutive impact of recent acquisitions and collaborations.&nbsp; The Zacks Consensus Estimate for 2024 earnings per share is pegged at $0.61.</p>
<p>Revenues are anticipated to increase in the low single digits (no change).</p>
<div class="chart_embed">
<p><strong>Bristol Myers Squibb Company Price, Consensus and EPS Surprise </strong></p>
<p><a href="https://www.zacks.com/stock/chart/BMY/price-consensus-eps-surprise-chart?icid=chart-BMY-price-consensus-eps-surprise-chart"><img alt="Bristol Myers Squibb Company Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/cb/1714058530.png" style="height:265px; width:576px" title="" /> </a></p>
<p>Bristol Myers Squibb Company price-consensus-eps-surprise-chart | Bristol Myers Squibb Company Quote</p>
</div>
<h3>Recent Acquisitions</h3>
<p>In January 2024, BMY acquired Mirati Therapeutics, further diversifying its oncology portfolio. The acquisition added commercialized lung cancer medicine, Krazati, to its oncology portfolio, as well as several promising clinical assets.</p>
<p>During the quarter, Bristol Myers acquired Karuna Therapeutics, Inc., Bristol Myers Squibb expanded its position in neuroscience and added important assets, including KarXT &mdash; an antipsychotic with a novel mechanism of action and differentiated efficacy and safety. The candidate is under review in the United States for the treatment of schizophrenia in adults, with a target action date of Sep 26, 2024.</p>
<p>BMY also acquired clinical-stage radiopharmaceutical therapeutics company RayzeBio, Inc. and gained a rich pipeline of potentially first-in-class and best-in-class drug development programs currently targeting solid tumors.</p>
<p>The company also completed an exclusive license and collaboration agreement with SystImmune to develop and commercialize a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate with the potential to treat a variety of solid tumors, including lung and breast cancers.</p>
<h3>Our Take</h3>
<p>Bristol-Myers&#39; reported better-than-expected first-quarter results as adjusted loss was narrower than expected and sales beat estimates. However, the decline in Opdivo sales was a dampener.&nbsp; Revlimid is already facing generic competition and Eliquis, too, is likely to face challenges later.</p>
<p>It remains to be seen how the growth in new drugs compensates for this decline in sales of these blockbuster drugs. The uptake of Reblozyl has been strong but it is still a long way to go for BMY when its new drugs start contributing significantly.</p>
<p>Along with the earnings release, Bristol Myers also announced that it is undertaking a strategic productivity initiative that will drive approximately $1.5 billion in cost savings by the end of 2025.</p>
<h3>Zacks Rank &amp; Stocks to Consider</h3>
<p>Bristol-Myers currently carries a Zacks Rank #3 (Hold).</p>
<p>A couple of better-ranked stocks in the biotech sector are <strong>ADMA Biologics, Inc</strong>. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adma#NASDAQ">ADMA</a>)&nbsp;and <strong>ANI Pharmaceuticals, Inc</strong>. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anip#NASDAQ">ANIP</a>), both sporting a Zacks Rank #1 (Strong Buy) at present.</p>
<p>In the past 60 days, estimates for ADMA Biologics&#39; 2024 earnings per share (ETF:EPS) have improved from 22 to 30 cents. Shares of ADMA have rallied 40.9% year to date.</p>
<p>ADMA&#39;s earnings beat estimates in three of the trailing four quarters and met the same once, delivering an average surprise of 85.00%.</p>
<p>In the past 60 days, estimates for ANI Pharmaceuticals&#39; 2024 EPS have improved from $4.12 to $4.43. Shares of ANIP have jumped 17.3% year to date.</p>
<p>ANIP&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 109.06%.<br />
<a href="https://www.zacks.com/stock/news/2262623/bristol-myers-bmy-q1-loss-narrower-than-expected-sales-beat?cid=CS-BENZ-FT-analyst_blog|earnings_article-2262623">To read this article on Zacks.com click here.</a></p>


<p>Shares of <strong>Moderna</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) rose 6.2% on Apr 9 after management announced encouraging data from a portion of an early-stage study on mRNA-4157/V940, its investigational individualized neoantigen therapy, in certain patients with head and neck cancer. The INT is being developed in collaboration with <strong>Merck </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mrk#NYSE">MRK</a>).</p>
<p>This portion of the study evaluated the combination of mRNA-4157 and Merck&#39;s blockbuster immuno-oncology drug Keytruda in patients with human papillomavirus negative (HPV-) head and neck squamous cell carcinoma (HNSCC).</p>
<p>Data from the study showed that treatment with the combination not only achieved positive clinical responses in HPV- HNSCC patients but even showed evidence of activation of immune responses. The combined therapy was also found to be safe and well-tolerated by study participants.</p>
<p>Per management, treatment with the combination achieved an objective response rate (ORR) in six out of 22 patients, including two complete responses and four partial ones. The disease control rate was 63.6%. These results were presented at the American Society of Cataract and Refractive Surgery (ASCRS) earlier this week.</p>
<p>Moderna and Merck are already evaluating mRNA-4157 in two separate pivotal late-stage studies in melanoma and non-small cell lung cancer (NSCLC) indications. The companies intend to expand mRNA-4157 across multiple oncology indications and also start more clinical studies throughout this year. Last month, Moderna/Merck posted details on a government website of a phase II/III study evaluating the INT in patients with cutaneous squamous cell carcinoma (CSCC), a form of skin cancer.</p>
<p>Merck and Moderna entered a strategic partnership in 2016 to develop and market mRNA-based therapeutics to treat various types of cancer. Per the terms of the collaboration, the companies will share costs and profits equally.</p>
<p>Year to date, Moderna&#39;s shares have gained 12.2% against the industry&#39;s 5.4% fall.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/00/64728.jpg?v=18184968" /><br />
Image Source: Zacks Investment Research</p>
<p>Unlike other therapies that are uniformly designed to treat all patients, the INT aims to bring individualized treatment to cancer patients. mRNA-4157 is tailored for each patient based on the unique mutational signature of a patient&#39;s tumor.</p>
<p>As opposed to traditional medications, mRNA-based therapies teach the body how to make a specific protein that can help your immune system prevent or treat certain diseases. The COVID-19 pandemic further demonstrated the significant potential of mRNA-based therapeutics. By way of COVID-19 vaccines, mRNA vaccines have generated immune responses against the virus at record-high levels compared with traditional protein-based and adeno-based vaccines.</p>
<p>Currently, Moderna has only one commercial product, its COVID-19 vaccine, which is currently facing a steep/significant decline in revenues, ever since the pandemic ended. Using the robust cash sales generated during the pandemic years, Moderna has significantly accelerated its pipeline development, which has shown high clinical efficacy across multiple different indications.</p>
<p>Moderna plans to launch 15 new marketed products, including four in rare disease indications, over the next five years. These include vaccines for RSV, CMV and influenza. Management expects potential FDA approval for its RSV vaccine mRNA-1345 in June. If approved, mRNA-1345 could be Moderna&#39;s second product launch, whose commercial launch is expected in the third quarter of 2024.</p>
<p>Management believes that the company&#39;s vaccine portfolio targets large addressable markets with an estimated total addressable market&nbsp;of around $52 billion for infectious disease vaccines.</p>
<div class="chart_embed">
<h3>Moderna, Inc. Price</h3>
<p><a href="https://www.zacks.com/stock/chart/MRNA/fundamental/price?icid=chart-MRNA-fundamental/price"><img alt="Moderna, Inc. Price" src="https://staticx-tuner.zacks.com/images/charts/16/1712748428.png" style="height:251px; width:543px" title="" /> </a></p>
<p>Moderna, Inc. price | Moderna, Inc. Quote</p>
</div>
<h3>Zacks Rank &amp; Key Picks</h3>
<p>Moderna currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the overall healthcare sector include <strong>ADMA Biologics </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adma#NASDAQ">ADMA</a>) and <strong>ANI Pharmaceuticals </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anip#NASDAQ">ANIP</a>), each sporting a Zacks Rank #1 (Strong Buy).</p>
<p>In the past 60 days, estimates for ADMA Biologics&#39; 2024 earnings per share have risen from 22 cents to 30 cents. During the same period, EPS estimates for 2025 have improved from 32 cents to 50 cents. Year to date, shares of ADMA have surged 35.2%.</p>
<p>Earnings of ADMA Biologics beat estimates in three of the last four quarters while meeting the same on one occasion. ADMA delivered a four-quarter average earnings surprise of 85.00%.</p>
<p>In the past 60 days, estimates for ANI Pharmaceuticals&#39; 2024 EPS have risen from $4.06 to $4.43. Meanwhile, during the same period, EPS estimates for 2025 have improved from $4.80 to $5.04. Year to date, shares of ANIP have risen 21.6%.</p>
<p>Earnings of ANI Pharmaceuticals beat estimates in each of the last four quarters. ANI delivered a four-quarter average earnings surprise of 109.06%.</p>
<p><a href="https://www.zacks.com/stock/news/2253502/moderna-mrna-up-6-on-upbeat-data-from-cancer-jab-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-2253502">To read this article on Zacks.com click here.</a></p>


<p>ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $7.75, with a high estimate of $10.00 and a low estimate of $6.00. Witnessing a positive shift, the current average has risen by 15.67% from the previous average price target of $6.70.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1711454429_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A clear picture of ADMA Biologics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$7.50</td>
<td>$6.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$10.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$6.50</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.00</td>
<td>-</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$9.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$6.00</td>
<td>$5.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ADMA Biologics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ADMA Biologics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for ADMA Biologics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of ADMA Biologics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ADMA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on ADMA Biologics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About ADMA Biologics</h2>
<p>ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.</p>
<h3>Key Indicators: ADMA Biologics's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> ADMA Biologics's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of <strong>47.86%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> ADMA Biologics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-23.88%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> ADMA Biologics's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-12.31%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> ADMA Biologics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-5.2%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>1.05</strong>, caution is advised due to increased financial risk.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

A Closer Look at 6 Analyst Recommendations For ADMA Biologics

<p>HC Wainwright &amp; Co.  analyst Raghuram Selvaraju   reiterates ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) with a Buy and raises the price target from $6 to $7.5.</p>


Price Target

Reiteration

HC Wainwright & Co. Reiterates Buy on ADMA Biologics, Raises Price Target to $7.5

<p>The room temperature approval applies to all existing ASCENIV and BIVIGAM lots currently in the commercial supply chain as well as to future production of ASCENIV and BIVIGAM.</p>


ADMA Biologics Reports FDA Approvals Of Extended Room Temperature Storage Conditions For ASCENIV & BIVIGAM

<p>Piper Sandler  analyst Anthony Petrone   maintains ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) with a Buy and raises the price target from $9 to $10.</p>


Piper Sandler Maintains Buy on ADMA Biologics, Raises Price Target to $10

<p>Cantor Fitzgerald  analyst Kristen Kluska   maintains ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) with a Overweight and raises the price target from $6.5 to $8.</p>


Cantor Fitzgerald Maintains Overweight on ADMA Biologics, Raises Price Target to $8

<p>Analysts' ratings for ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for ADMA Biologics, revealing an average target of $6.75, a high estimate of $9.00, and a low estimate of $6.00. This upward trend is evident, with the current average reflecting a 12.5% increase from the previous average price target of $6.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1709218858_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The perception of ADMA Biologics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.00</td>
<td>-</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$9.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$6.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$6.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ADMA Biologics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of ADMA Biologics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for ADMA Biologics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into ADMA Biologics's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ADMA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on ADMA Biologics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind ADMA Biologics</h2>
<p>ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.</p>
<h3>Financial Milestones: ADMA Biologics's Journey</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> ADMA Biologics's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2023, the company achieved a revenue growth rate of approximately <strong>63.72%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> ADMA Biologics's net margin is impressive, surpassing industry averages. With a net margin of <strong>3.81%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> ADMA Biologics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>1.72%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> ADMA Biologics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.74%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> ADMA Biologics's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>1.01</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Forecasting The Future: 4 Analyst Projections For ADMA Biologics

<p>HC Wainwright &amp; Co.  analyst Raghuram Selvaraju   reiterates ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) with a Buy and maintains $6 price target.</p>


HC Wainwright & Co. Reiterates Buy on ADMA Biologics, Maintains $6 Price Target

Guidance

ADMA Biologics Sees FY24 And FY25 Total Revenue Above $330M And $380M, Respectively, Up From Prior Guidance Of $320M And $370M, Respectively

<p><strong>ADMA Biologics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) reported its Q4 earnings results on Wednesday, February 28, 2024 at 04:05 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>ADMA Biologics beat estimated earnings by 100.0%, reporting an EPS of $0.04 versus an estimate of $0.02.</p>
<p>Revenue was up $23.92 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat on EPS by $0.02 which was followed by a 6.0% increase in the share price the next day.</p>
<p>Here's a look at ADMA Biologics's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2023</strong></th>
<th><strong>Q2 2023</strong></th>
<th><strong>Q1 2023</strong></th>
<th><strong>Q4 2022</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.01</td>
<td>-0.02</td>
<td>-0.04</td>
<td>-0.06</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.01</td>
<td>-0.03</td>
<td>-0.03</td>
<td>-0.06</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>62.12M</td>
<td>55.50M</td>
<td>53.41M</td>
<td>45.93M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>67.28M</td>
<td>60.12M</td>
<td>56.91M</td>
<td>49.98M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for ADMA Biologics <a href="https://www.benzinga.com/quote/ADMA/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

Recap: ADMA Biologics Q4 Earnings

<p>ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.03 by 33.33 percent.  The company reported quarterly sales of $73.90 million which beat the analyst consensus estimate of $72.15 million by 2.43 percent.  This is a 47.86 percent increase over sales of $49.98 million the same period last year.</p>


Earnings Beats

ADMA Biologics Q4 2023 Adj EPS $0.04 Beats $0.03 Estimate, Sales $73.90M Beat $72.15M Estimate

<p>Grossman has been appointed as Interim Chief Financial Officer, effective April 1, 2024. The Company has initiated an executive search for a full-time replacement Chief Financial Officer.</p>


Management

ADMA Biologics Says Brian Lenz, Executive Vice President, CFO & General Manager, ADMA BioCenters Will Be Transitioning From These Positions To A Consulting Role, Effective April 1, 2024

<p><strong>ADMA Biologics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-02-28. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that ADMA Biologics will report an <strong>earnings per share</strong> (EPS) of $0.02. </p>
<p>ADMA Biologics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Historical Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.02, which was followed by a 5.8% increase in the share price the next day.</p>
<p>Here's a look at ADMA Biologics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2023</strong></th>
<th><strong>Q2 2023</strong></th>
<th><strong>Q1 2023</strong></th>
<th><strong>Q4 2022</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.01</td>
<td>-0.02</td>
<td>-0.04</td>
<td>-0.06</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.01</td>
<td>-0.03</td>
<td>-0.03</td>
<td>-0.06</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>6.0%</td>
<td>6.0%</td>
<td>11.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1709060471_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of ADMA Biologics were trading at $5.4 as of February 26. Over the last 52-week period, shares are up 53.77%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/ADMA/earnings"><strong>To track all earnings releases for ADMA Biologics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Preview For ADMA Biologics

<ul>
<li>ADMAlytics Combines Generative AI and Machine Learning to Optimize Production Processes</li>
<li>ADMA Successfully Utilized ADMAlytics&#39; New Capabilities for the First Time to Automate and Realize Efficiency Improvements for Commercial Production Plasma Pooling</li>
<li>Broader Implementation of ADMAlytics Expected to Provide Efficiencies Across the Organization</li>
</ul>


ADMA Biologics Announced Successful Initial Use Of Its Artificial Intelligence Program, Named Admalytics

<p>In the latest quarter, 4 analysts provided ratings for ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated ADMA Biologics and provided 12-month price targets. The average target is $6.5, accompanied by a high estimate of $9.00 and a low estimate of $5.00. This current average has increased by 8.33% from the previous average price target of $6.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1705935621_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The standing of ADMA Biologics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$9.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$6.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$6.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to ADMA Biologics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of ADMA Biologics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of ADMA Biologics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into ADMA Biologics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ADMA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on ADMA Biologics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering ADMA Biologics: A Closer Look</h2>
<p>ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.</p>
<h3>Understanding the Numbers: ADMA Biologics's Finances</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Positive Revenue Trend:</strong> Examining ADMA Biologics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>63.72%</strong> as of 30 September, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> ADMA Biologics's net margin is impressive, surpassing industry averages. With a net margin of <strong>3.81%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> ADMA Biologics's ROE excels beyond industry benchmarks, reaching <strong>1.72%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> ADMA Biologics's ROA excels beyond industry benchmarks, reaching <strong>0.74%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> ADMA Biologics's debt-to-equity ratio surpasses industry norms, standing at <strong>1.01</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Cracking The Code: Understanding Analyst Reviews For ADMA Biologics

<p>Mizuho  analyst Anthony Petrone   maintains ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) with a Buy and raises the price target from $7 to $9.</p>


Mizuho Maintains Buy on ADMA Biologics, Raises Price Target to $9

<p>HC Wainwright &amp; Co.  analyst Raghuram Selvaraju   maintains ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) with a Buy and raises the price target from $5 to $6.</p>


HC Wainwright & Co. Maintains Buy on ADMA Biologics, Raises Price Target to $6

<p><strong>2024-2025 Financial&nbsp;Guidance:</strong></p>
<ul>
<li>FY 2024-2025 Total Revenue expected to be in the range of&nbsp;$320 Million&nbsp;to&nbsp;$370 Million, respectively, increased from&nbsp;$290 Million&nbsp;and&nbsp;$335 Million&nbsp;previously.</li>
<li>FY 2024-2025 Net Income expected to exceed&nbsp;$60 Million&nbsp;to&nbsp;$110 Million, respectively, increased from&nbsp;$55 Million&nbsp;and&nbsp;$100 Million&nbsp;previously.</li>
<li>FY 2024 Adjusted EBITDA anticipated to reach&nbsp;$85 Million&nbsp;or more.</li>
</ul>


ADMA Biologics' 4Q 2023 Preliminary Unaudited Total Revenue of $72M-74M Versus Consensus Of $68.49M; FY 2023 Preliminary Unaudited Total Revenue of $256M-258M Versus Consensus Of $252.79M

<p>Cantor Fitzgerald  analyst Kristen Kluska   reiterates ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) with a Overweight and maintains $6 price target.</p>


Cantor Fitzgerald Reiterates Overweight on ADMA Biologics, Maintains $6 Price Target

ADMA Biologics GAAP EPS of -$0.08 misses by $0.11, revenue of $73.9M beats by $0.93M

ADMA Biologics' CFO to step down

ADMA Biologics (ADMA) has issued an announcement. ADMA Biologics, Inc. has made key decisions regarding executive compensation, including approving...

ADMA Biologics Enhances Executive Compensation and Seeks New CFO

ADMA Biologics, Inc. (ADMA) Q4 2023 Earnings Call Transcript

ADMA Biologics (ADMA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H....

Buy Rating Affirmed for ADMA Biologics Amidst Strong Financial Growth and Positive Long-Term Outlook

ADMA Biologics Inc (ADMA) has risen Thursday morning, with the stock gaining 2.12% in pre-market trading to 6.25. ADMA's short-term technical score of 93 indicates that the stock has traded more bullishly over the last month than 93% of stocks on the market. In the Biotechnology industry, which ranks 89 out of 146 industri

ADMA Biologics Inc (ADMA) Up 2.12% in Premarket Trading

A rating of 88 puts ADMA Biologics Inc (ADMA) near the top of the Biotechnology industry according to InvestorsObserver. ADMA Biologics Inc's score of 88 means it scores higher than 88% of stocks in the industry. ADMA Biologics Inc also received an overall rating of 74, putting it above 74% of all stocks. Biotechnology is

Should You Buy ADMA Biologics Inc (ADMA) in Biotechnology Industry?

ADMA Biologics Poised for Robust Growth: Buy Rating Affirmed with Enhanced Price Target

ADMA Biologics (ADMA) has shared an update. Kaitlin Kestenberg has been promoted to Chief Operating Officer and Senior Vice President, Compliance a...